Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions
Not listed
Lead sponsor
ElMindA Ltd
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
The Villages, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

NCT05655195
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Interventions
GENUS device (Active Settings), GENUS device (sham settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
65 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Alzheimer Disease, Early Onset
Interventions
Multivitamin-no intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

NCT04122001
Conditions
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
Interventions
Active, in-person HD-tDCS or active remote tDCS, Sham, Word List Learning Intervention (WordLLI)
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational

Tau Imaging in Young Onset Dementia

NCT02289118
Conditions
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions
[18F]-T807 imaging tracer
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Conditions
Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild, Alzheimer Disease, Alzheimer Disease, Early Onset
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years to 95 Years
Enrollment
100 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of PTI-125 in Healthy Volunteers

NCT03784300
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Alzheimer Disease, Early Onset
Interventions
AD-35 60mg group, Placebo group
Drug
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more
Enrolling by invitation Not applicable Interventional

Cholinergic Deep Brain Stimulation for Alzheimer's Disease

NCT05882344
Conditions
Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
Interventions
Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
Procedure · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Alzheimer Disease, Early Onset
Interventions
BMS-986446, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
119
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Familial Dementia

NCT04680013
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions
Non-interventional observational prospective cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more
Conditions
Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
Interventions
Personalized tDCS, Active-Sham
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Roslindale, Massachusetts
Conditions
Alzheimer Disease, Early Onset
Interventions
Cognitive Training, Tai Chi- Qi Gong, Brain Games, Stretching
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Interventions
lecanemab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 1 more
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more